BMS-P5 free base

Research use only, not for human use.

BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.

BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression Targeting PAD4 may be beneficial for treatment of multiple myeloma.Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression.

Cell Viability Assay.Cell Line:Neutrophils.Concentration:10 μM and 100 μM.Incubation Time:30 min followed by addition of DP42 or 5TGM1 CM.Result:Prevented MM-induced NET formation.

Animal Model:Syngeneic mouse model of MM.Dosage:50 mg/kg.Administration:Oral gavage, twice a day beginning on day 3 after tumor cell injection.Result:Significantly delayed development of symptoms and significantly prolonged survival of MM-bearing mice.

——

Others

Other Targets

peptidylarginine deiminase 4 (PAD4)

——

——

1550371-22-6

472.58

C27H32N6O2

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (529.01 mM)

O=C(N1[C@@H](C)CC[C@@H](N)C1)C2=CC(OC)=C3C(N=C(C4=CC5=CC=CN=C5N4CC6CC6)N3C)=C2

——

(-20℃)

With Ice Pack

≥ 2 years